Received Feb 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
possible organ transplant; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of organ transplant in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose on unknown date). Concurrent medical conditions included chemotherapy. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced organ transplant (Verbatim: possible organ transplant). The outcome of the organ transplant was unknown. It was unknown if the reporter considered the organ transplant to be related to Shingrix. It was unknown if the company considered the organ transplant to be related to Shingrix. Additional Information: GSK Receipt Date: 28-JAN-2026 The pharmacist inquired about a patient who was currently receiving chemotherapy and the 1st Shingrix series was completed (prior to chemotherapy). The pharmacist thought the patient might have received an organ transplant. When asked about possible cancer type or organ transplant type, the pharmacist did not have any further details. The batch number was not provided upon follow- up with the reporter. Follow up received on 19-FEB-2026 As per follow up information received it was reported that country of occurrence was one country not another county. Summary of changes: Reporter information, patient information, product details, event details and narrative were updated.
Chemotherapy